Table 1.
Univariate analysis of gene copy number and expression levels of MYC, MYCN and MYCL1 in EOC
| Serous EOC (n = 150) |
Endometrioid EOC (n = 80) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PFS |
OS |
PFS |
OS |
|||||||
| Gene | No. of cases | HR (95% CI) | P* | HR (95% CI) | P | No. of cases | HR (95% CI) | P | HR (95% CI) | P |
| MYC | ||||||||||
| Gain | 11 | 0.99 (0.70 to 1.39) | .94 | 0.93 (0.59 to 1.47) | .75 | 0 | — | — | — | — |
| Amplification | 24 | 1.23 (0.78 to 1.96) | .38 | 0.92 (0.49 to 1.70) | .79 | 10 | 1.11 (0.38 to 3.23) | .85 | 0.66 (0.15 to 2.87) | .58 |
| MYCN | ||||||||||
| Gain | 0 | — | — | — | — | 0 | — | — | — | — |
| Amplification | 0 | — | — | — | — | 0 | — | — | — | — |
| MYCL1 | ||||||||||
| Gain | 0 | — | — | — | — | 0 | — | — | — | — |
| Amplification | 9 | 1.64 (0.80 to 3.36) | .18 | 1.56 (0.68 to 3.6) | .29 | 1 | ND | ND | ND | ND |
| Any Myc gene alteration | 44 | 1.28 (0.87 to 1.88) | .20 | 1.04 (0.64 to 1.69) | .88 | 11 | 0.97 (0.33 to 2.82) | .95 | 0.59 (0.14 to 2.57) | .48 |
| Overexpression | ||||||||||
| MYC | MED | 1.04 (0.73 to 1.48) | .84 | 1.12 (0.73 to 1.74) | .60 | MED | 1.37 (0.63 to 2.94) | .43 | 1.69 (0.66 to 4.34) | .27 |
| MYCN | LQ | 0.89 (0.59 to 1.32) | .55 | 1.51 (0.68 to 1.95) | .60 | LQ | 1.92 (0.66 to 5.60) | .22 | 1.02 (0.34 to 3.10) | .97 |
| MYCL1 | LQ | 0.82 (0.55 to 1.23) | .06 | 0.70 (0.42 to 1.12) | .13 | MED | 2.06 (0.92 to 4.64) | .07 | 2.22 (0.87 to 5.63) | .09 |
*
Log-rank P value. PFS = progression-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval; ND = not determined; MED = Medium; LQ = Lower Quartile.